(*) JP Approval Date: 2022. 08.25
(*) USA Approval Date: 2022. 04.28
>MAb
Company
Company Parent
Generic Name: Ravulizumab
gMG: Myasthemia Gravis generalized
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 5
Patent>UpDate: 2022. 06.28
RTM
RTM Web-Site